2 weeks Ago By ABMN Staff
Forsta AP Fonden cut its holdings in Quest Diagnostics Incorporated ( NYSE:DGX – Free Report ) by 21.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,300 shares of the medical research company’s stock after selling 7,000 shares during the quarter.
Forsta AP Fonden’s holdings in Quest Diagnostics were worth $3,463,000 as of its most recent filing with the SEC. A number of other institutional investors also recently bought and sold shares of DGX. Rothschild Investment LLC acquired a new position in Quest Diagnostics in the second quarter valued at $26,000.
Spartan Planning & Wealth Management acquired a new position in shares of Quest Diagnostics during the fourth quarter worth about $31,000. Innealta Capital LLC acquired a new position in shares of Quest Diagnostics during the second quarter worth about $31,000. Larson Financial Group LLC increased its stake in shares of Quest Diagnostics by 77.
5% during the second quarter. Larson Financial Group LLC now owns 229 shares of the medical research company’s stock worth $31,000 after acquiring an additional 100 shares during the period. Finally, Riverview Trust Co acquired a new position in shares of Quest Diagnostics during the first quarter worth about $33,000.
88.06% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth DGX has been the topic of a number of recent analyst reports.
Evercore ISI initiated coverage on shares of Quest Diagnostics in a research note on Wednesday, August 28th. They set an “in-line” rating and a $165.00 price target on the stock.
Truist Financial boosted their price target on shares of Quest Diagnostics from $150.00 to $158.00 and gave the stock a “hold” rating in a research note on Monday, July 15th.
Citigroup upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $145.00 to $165.00 in a research report on Wednesday, July 10th.
StockNews.com upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd. Finally, Piper Sandler upped their target price on shares of Quest Diagnostics from $145.
00 to $150.00 and gave the stock a “neutral” rating in a research report on Monday, July 29th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company.
According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $154.33. Quest Diagnostics Trading Down 0.
2 % Quest Diagnostics stock opened at $154.38 on Monday. The firm’s 50-day moving average is $149.
21 and its 200-day moving average is $140.04. The company has a debt-to-equity ratio of 0.
57, a quick ratio of 0.91 and a current ratio of 1.00.
Quest Diagnostics Incorporated has a 1 year low of $119.59 and a 1 year high of $159.36.
The company has a market cap of $17.19 billion, a P/E ratio of 20.78, a PEG ratio of 2.
80 and a beta of 0.89. Quest Diagnostics ( NYSE:DGX – Get Free Report ) last issued its quarterly earnings data on Tuesday, July 23rd.
The medical research company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.31 by $0.
04. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.
39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.
35%. Quest Diagnostics’s quarterly revenue was up 2.5% compared to the same quarter last year.
During the same period last year, the firm posted $2.30 EPS. On average, equities analysts expect that Quest Diagnostics Incorporated will post 8.
89 earnings per share for the current year. Quest Diagnostics Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 21st. Investors of record on Friday, October 4th will be given a $0.
75 dividend. The ex-dividend date of this dividend is Friday, October 4th. This represents a $3.
00 annualized dividend and a yield of 1.94%. Quest Diagnostics’s dividend payout ratio is presently 40.
38%. Insider Activity at Quest Diagnostics In related news, SVP Mark E. Delaney sold 420 shares of Quest Diagnostics stock in a transaction dated Wednesday, July 24th.
The shares were sold at an average price of $143.08, for a total value of $60,093.60.
Following the sale, the senior vice president now directly owns 5,019 shares in the company, valued at approximately $718,118.52. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website .
In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,990 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total transaction of $304,987.
40. Following the transaction, the senior vice president now owns 11,459 shares of the company’s stock, valued at approximately $1,756,206.34.
The transaction was disclosed in a filing with the SEC, which can be accessed through this link . Also, SVP Mark E. Delaney sold 420 shares of the firm’s stock in a transaction dated Wednesday, July 24th.
The shares were sold at an average price of $143.08, for a total transaction of $60,093.60.
Following the transaction, the senior vice president now directly owns 5,019 shares in the company, valued at approximately $718,118.52. The disclosure for this sale can be found here .
0.79% of the stock is currently owned by insiders. Quest Diagnostics Profile ( Free Report ) Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally.
The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. Featured Stories Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated ( NYSE:DGX – Free Report ).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter ..
